Pluristem Therapeutics Raises Approximately $5 Million In Private Placement Of Common Stock
Pluristem Therapeutics Inc. (Nasdaq: PSTI) (DAX: PJT) today announced
that it has entered into definitive agreements with selected
institutional and private investors to sell restricted common stock and
Pluristem Therapeutics Inc. (Nasdaq: PSTI) (DAX: PJT) today announced that it has entered into definitive agreements with selected institutional and private investors to sell restricted common stock and warrants for aggregate gross proceeds of approximately $5.25 million. The offering includes 4,375,000 shares of common stock at a per share purchase price of $1.20 and four year warrants to purchase 2,625,000 shares of common stock at an exercise price of $1.80 per share, exercisable six months following the issuance thereof. The closing is scheduled to take place no later than October 18, 2010. The shares of common stock and warrants being sold in the private placement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended, and applicable state securities laws. The company agreed to file a resale registration statement covering the shares and warrant shares sold in the private placement within 60 days from closing. Leader Underwriters (1993) Ltd, acted as the Israeli placement agent for the transaction. Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as the U.S. placement agent for the transaction. This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any security and shall not constitute any offer, solicitation or sale in any jurisdiction in which such offering would be unlawful. About Pluristem Pluristem is a clinical stage biotechnology company with patented technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem's proprietary and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases.